-
<![CDATA[Ozempic Shows Greater Effect in Reducing Stroke, Heart Attack Risk Over Competitor Dulaglutide]]>
24 Sep 2025 00:13 GMT
… , findings showed that semaglutide (Ozempic; Novo Nordisk), an FDA-approved glucagon-like … and diabetes, outperformed dulaglutide, a competitor GLP-1 RA, in lowering … and cardiovascular disease. News release. Novo Nordisk. August 31, 2025. Accessed September …
-
Can oral GLP-1RAs deliver on the promise of accessible obesity care?
23 Sep 2025 14:39 GMT
… accessible for patients.
Both Novo Nordisk and Eli Lilly have … .
Find out more
In Novo Nordisk’s OASIS4 trial (NCT05035095), … ahead of regulatory approval.
Novo Nordisk’s oral semaglutide is already … definitely emerge as strong competitors. It really all comes …
-
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity
23 Sep 2025 12:30 GMT
… product candidates; new or existing competitors with greater resources and capabilities … ® is a registered trademark of Novo Nordisk A/S. Investor and …
-
Pfizer Bets Big with $7.3 Billion Metsera Acquisition to Dominate Weight-Loss Market
23 Sep 2025 08:27 GMT
… dominated by Eli Lilly and Novo Nordisk. With global obesity rising, this …
Market Leadership Gap: Compete with Novo Nordisk (Ozempic, Wegovy) and Eli Lilly … to $29.45. Competitors showed mixed reactions: Novo Nordisk dipped, while Viking Therapeutics …
-
Analysis-Innovent’s weight-loss drug highlights China challenge for Novo, Lilly
22 Sep 2025 23:29 GMT
… therapy available in China after Novo Nordisk’s Wegovy and Eli Lilly … have an impact on Western competitors,” said Tony Ren, head of …
-
Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More
22 Sep 2025 21:56 GMT
… the weekly injectables Wegovy, from Novo Nordisk, and Zepbound, from Eli Lilly … , such as the amylin receptor. Novo Nordisk has two programs in the … should yield tolerability advantages over competitors and also offer maximum flexibility …
-
Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight
22 Sep 2025 17:00 GMT
…
Key Thalassemia Companies
Agios Pharmaceuticals, Novo Nordisk, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, … for Thalassemia
11.1
Key Competitors
11.2
CASGEVY (exagamglogene … and actionable intelligence on their competitors and markets of interest …
-
DexCom is under fire from accusations
22 Sep 2025 16:02 GMT
… the G6 or switching to competitors, while the market is becoming … complex with GLP-1 treatments (Novo Nordisk, Eli Lilly) that are likely …
-
Pharmacotherapy for Obesity: Recent Updates
19 Sep 2025 09:19 GMT
… subcutaneous GLP-1 RA competitors are also being investigated. … Mills, Regeneron, Boehringer Ingelheim, Novo Nordisk, Currax, Structure Pharmaceutical, Eli … of Health, Vivus Pharmaceuticals, Novo-Nordisk, Apollo Endosurgery, Satiogen Pharmaceuticals, …
-
Is Pfizer Stock A Buy On Its Flashy $4.9 Billion Obesity Buyout?
17 May 2022 07:26 GMT
… catch Eli Lilly (LLY) and Novo Nordisk (NVO), the de facto leaders … .
Amgen (AMGN) is the closest competitor with a drug that mimics …
About
© 1995-2025